Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study. [artículo]
Por: Vera, Francisco [Cirugía Cardiovascular]
.
Colaborador(es): Instituto de Investigación imas12 | Servicio de Cirugía Cardiovascular.
Editor: HIV clinical trials, 2013Descripción: 14(5):204-15.Recursos en línea: Solicitar documento Resumen: OBJECTIVES: Current antiretroviral guidelines state that being older than 50 to 55 years of age is an indication to start antiretroviral therapy (ART), regardless of CD4 status. However, no references to the preferred combination ART (cART) for these patients have been described. Our study compares emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) versus other nucleoside reverse transcriptase inhibitor (NNRTI) regimens in HIV ART-naïve patients who are ≥50 years.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC3221 (Navegar estantería) | Disponible |
Formato Vancouver:
Blanco JR, Caro-Murillo AM, Castaño MA, Olalla J, Domingo P, Arazo P et al. Safety, efficacy, and persistence of
emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study. HIV Clin Trials. 2013 Sep-Oct;14(5):204-15.
PMID: 24144897
Contiene 43 referencias
OBJECTIVES: Current antiretroviral guidelines state that being older than 50 to 55 years of age is an indication to start antiretroviral therapy (ART), regardless of CD4 status. However, no references to the preferred combination ART (cART) for these patients have been described. Our study compares emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) versus other nucleoside reverse transcriptase inhibitor (NNRTI) regimens in HIV ART-naïve patients who are ≥50 years.
No hay comentarios para este ejemplar.